Lexaria Bioscience Corp Cash Flow Conversion Efficiency
Lexaria Bioscience Corp cash flow conversion efficiency. Based on the latest financial reports, Lexaria Bioscience Corp (LEXXW) has a cash flow conversion efficiency ratio of -0.218x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-984.10K) by net assets ($4.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lexaria Bioscience Corp (2005–2025)
Cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. This chart illustrates how Lexaria Bioscience Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LEXXW stock price for real-time trading data and today's change.
Lexaria Bioscience Corp Cash Flow Conversion Ratio Explained
Lexaria Bioscience Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lexaria Bioscience Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexaria Bioscience Corp ranked by their cash flow conversion efficiency. Also see market cap of Lexaria Bioscience Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasmine International Public Company Limited
F:JASN
|
0.020x |
|
Clene Inc
NASDAQ:CLNNW
|
0.322x |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
-0.053x |
|
Liberty Metals Ltd
AU:LIB
|
N/A |
|
Aquis Exchange PLC
LSE:AQX
|
0.057x |
|
Waldencast Acquisition Corp
NASDAQ:WALDW
|
-0.003x |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
-0.270x |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. Review Lexaria Bioscience Corp free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.60 Million | $-10.45 Million | -4.015x | -520.13% |
| 2024-08-31 | $7.66 Million | $-4.96 Million | -0.647x | +70.49% |
| 2023-08-31 | $2.68 Million | $-5.88 Million | -2.194x | -243.26% |
| 2022-08-31 | $7.63 Million | $-4.88 Million | -0.639x | -109.32% |
| 2021-08-31 | $13.06 Million | $-3.99 Million | -0.305x | +71.05% |
| 2020-08-31 | $2.48 Million | $-2.62 Million | -1.055x | +12.57% |
| 2019-08-31 | $2.49 Million | $-3.01 Million | -1.207x | -14.45% |
| 2018-08-31 | $2.39 Million | $-2.52 Million | -1.054x | -88.77% |
| 2017-08-31 | $2.77 Million | $-1.55 Million | -0.559x | +92.58% |
| 2016-08-31 | $87.76K | $-660.86K | -7.531x | -229.41% |
| 2015-08-31 | $656.60K | $-1.50 Million | -2.286x | -1594.78% |
| 2014-08-31 | $2.10 Million | $321.00K | 0.153x | 0.00% |
| 2013-08-31 | $2.10 Million | $321.00K | 0.153x | +6.02% |
| 2012-08-31 | $2.23 Million | $321.00K | 0.144x | +182.41% |
| 2011-08-31 | $2.66 Million | $135.94K | 0.051x | +11.09% |
| 2010-08-31 | $2.39 Million | $109.84K | 0.046x | +130.70% |
| 2009-08-31 | $2.21 Million | $-330.34K | -0.150x | -913.10% |
| 2008-08-31 | $2.46 Million | $-36.40K | -0.015x | -272.88% |
| 2007-08-31 | $3.39 Million | $29.04K | 0.009x | +102.76% |
| 2006-08-31 | $704.55K | $-218.56K | -0.310x | -120.33% |
| 2005-08-31 | $1.09 Million | $-153.38K | -0.141x | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more